Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.
Rebecca Gardner(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Christopher Brown, Wenjun Huang(Lishui Central Hospital), Kirk R. Schultz(University of British Columbia), Corinne Summers(Seattle Children's Hospital), Prabha Narayanaswamy, Stephanie Mgebroff(Bloodworks Northwest), Colleen Annesley(Unknown), Adam Johnson(Sana Biotechnology (United States)), Catherine Lindgren(Unknown), Vicky Wu(Fred Hutch Cancer Center), Amanda Li(BC Children's Hospital)
Cited by 13
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754